A Pfizer Analysis Makes The Case For A COVID Vaccine Booster

A health care worker administers a third dose of the Pfizer-BioNTech COVID-19 vaccine at a senior living facility in Worcester, Pa., in August.

Pfizer says data supports its request for Food and Drug Administration approval of a third dose of the COVID-19 vaccine about six months after the second dose in people 16 years and older.

(Image credit: Hannah Beier/Bloomberg via Getty Images)


Leave a Reply

Your email address will not be published. Required fields are marked *